| Ticker Details |
Rockwell Medical, Inc. (DE) Common Stock
Rockwell Medical Inc is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease with its products and services for the treatment of iron deficiency, secondary hyperparathyroidism, and hemodialysis.
|
| IPO Date: |
February 1, 1998 |
| Sector: |
Healthcare |
| Industry: |
Health Care Equipment and Supplies |
| Market Cap: |
$37.44M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.07 | 3.86%
|
| Avg Daily Range (30 D): |
$0.04 | 3.66%
|
| Avg Daily Range (90 D): |
$0.03 | 3.03%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.49M |
| Avg Daily Volume (30 D): |
1.01M |
| Avg Daily Volume (90 D): |
.55M |
| Trade Size |
| Avg Trade Size (Sh.): |
242 |
| Avg Trade Size (Sh.) (30 D): |
311 |
| Avg Trade Size (Sh.) (90 D): |
328 |
| Institutional Trades |
| Total Institutional Trades: |
185 |
| Avg Institutional Trade: |
$1.17M |
| Avg Institutional Trade (30 D): |
$M |
| Avg Institutional Trade (90 D): |
$M |
| Avg Institutional Trade Volume: |
.02M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.46M |
| Avg Closing Trade (30 D): |
$M |
| Avg Closing Trade (90 D): |
$M |
| Avg Closing Volume: |
30.67K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-.18
|
$-.05
|
$-.05
|
|
Diluted EPS
|
$-.18
|
$-.05
|
$-.05
|
|
Revenue
|
$75.58M
|
$15.93M
|
$16.07M
|
|
Gross Profit
|
$11.45M
|
$2.27M
|
$2.5M
|
|
Net Income / Loss
|
$-5.52M
|
$-1.75M
|
$-1.49M
|
|
Operating Income / Loss
|
$-4.81M
|
$-1.58M
|
$-1.35M
|
|
Cost of Revenue
|
$64.13M
|
$13.66M
|
$13.57M
|
|
Net Cash Flow
|
$1.27M
|
$1.13M
|
$1.09M
|
|
PE Ratio
|
|
|
|
|
|
|